Fezolinetant and Dotinurad WC Certificate

Celebrating Shandong Loncom Pharmaceutical's Fezolinetant and Dotinurad Receiving WC Certificates.

Shandong Loncom Pharmaceutical is pleased to announce that Fezolinetant and Dotinurad, have successfully obtained WC. These certificates authorize the export of these high-quality pharmaceutical ingredients to the European Union.

Fezolinetant, a non-hormonal treatment developed for menopausal hot flashes, and Dotinurad, a novel urate transporter inhibitor used for hyperuricemia and gout, have both met the EU's stringent requirements for quality, safety, and Good Manufacturing Practice (GMP). The Written Confirmation underscores Loncom Pharmaceutical's commitment to manufacturing excellence and its capability to supply materials that satisfy one of the world's most rigorous regulatory frameworks.

If you need these APIs to Research your finished product, please contact us.